Pulmonary hypertension natural history: Difference between revisions
Jump to navigation
Jump to search
m (Robot: Changing Category:Disease state to Category:Disease) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Pulmonary hypertension}} | {{Pulmonary hypertension}} | ||
{{CMG}} '''Assistant Editor(s)-in-Chief:''' [[User:Ralph Matar|Ralph Matar]] | {{CMG}} '''Assistant Editor(s)-in-Chief:''' [[User:Ralph Matar|Ralph Matar]] | ||
==Overview== | |||
== | ==Natural History, Complications and Prognosis== | ||
*The National Institutes of Health (NIH)Registry estimated a median survival of 2.8 years for symptomatic patients with idiopathic pulmonary hypertension who do not recieve any treatment, with the cause of death usually being right ventricular failure ([[cor pulmonale]]). | *The National Institutes of Health (NIH)Registry estimated a median survival of 2.8 years for symptomatic patients with idiopathic pulmonary hypertension who do not recieve any treatment, with the cause of death usually being right ventricular failure ([[cor pulmonale]]). | ||
| Line 16: | Line 18: | ||
*It would not be unreasonable to expect median survival to extend past 10 years in the near future. | *It would not be unreasonable to expect median survival to extend past 10 years in the near future. | ||
===Prognosis=== | |||
==Prognosis== | |||
*The long-term prognosis has been known to be poor, however outcomes have changed dramatically over the last two decades. This may be attributed to the use of newer drug therapy, better overall care, and earlier diagnosis (lead time bias). | *The long-term prognosis has been known to be poor, however outcomes have changed dramatically over the last two decades. This may be attributed to the use of newer drug therapy, better overall care, and earlier diagnosis (lead time bias). | ||
| Line 24: | Line 25: | ||
Surprisingly, patients with [[Eisenmenger syndrome]] have a more favorable [[hemodynamic profile]] and prognosis than adults with idiopathic or primary pulmonary hypertension.<ref> Hopkins WE,Ochoa LL, Richardson GW, Trulock EP(1996) Comparison of the hemodynamics and survival or patients with severe pulmonary hypertension or Eisenmenger Syndrome.</ref> | Surprisingly, patients with [[Eisenmenger syndrome]] have a more favorable [[hemodynamic profile]] and prognosis than adults with idiopathic or primary pulmonary hypertension.<ref> Hopkins WE,Ochoa LL, Richardson GW, Trulock EP(1996) Comparison of the hemodynamics and survival or patients with severe pulmonary hypertension or Eisenmenger Syndrome.</ref> | ||
'''Indicators of Poor Prognosis''': | '''Indicators of Poor Prognosis''': | ||
| Line 36: | Line 36: | ||
*Decreased pulmonary arterial [[capacitance]]. | *Decreased pulmonary arterial [[capacitance]]. | ||
*Underlying [[Scleroderma]] or [[liver disease]]. | *Underlying [[Scleroderma]] or [[liver disease]]. | ||
==References== | ==References== | ||
| Line 42: | Line 41: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 18:27, 27 August 2012
|
Pulmonary Hypertension Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pulmonary hypertension natural history On the Web |
|
American Roentgen Ray Society Images of Pulmonary hypertension natural history |
|
Risk calculators and risk factors for Pulmonary hypertension natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Assistant Editor(s)-in-Chief: Ralph Matar
Overview
Natural History, Complications and Prognosis
- The National Institutes of Health (NIH)Registry estimated a median survival of 2.8 years for symptomatic patients with idiopathic pulmonary hypertension who do not recieve any treatment, with the cause of death usually being right ventricular failure (cor pulmonale).
- 1, 3,and 5-year survival rates for untreated patients with idiopathic pulmonary hypertension were 68%, 48%, and 34%, respectively. Studies from Japan,India and Mexico have suggested similar results.
- The median survival duration was even lower for patients with pulmonary hypertension that was associated with other diseases like portal hypertension, and Scleroderma(2-year survival of 40% if untreated).
- A recent outcome study of those patients who had started treatment with bosentan (Tracleer®) showed that 86% patients were alive at 3 years.
- With multiple agents now available, combination therapy is increasingly used. Impact of these agents on survival is not known, since many of them have been developed only recently.
- It would not be unreasonable to expect median survival to extend past 10 years in the near future.
Prognosis
- The long-term prognosis has been known to be poor, however outcomes have changed dramatically over the last two decades. This may be attributed to the use of newer drug therapy, better overall care, and earlier diagnosis (lead time bias).
- Some people with this condition may have heart failure that could lead to death. Assessment of prognosis in patients with pulmonary arterial hypertension (PAH) is important since it influences both medical therapy and referral for transplantation.
Surprisingly, patients with Eisenmenger syndrome have a more favorable hemodynamic profile and prognosis than adults with idiopathic or primary pulmonary hypertension.[1]
Indicators of Poor Prognosis:
- Age>45 at presentation.
- Poor exercise capacity.
- Elevated Brain Natriuretic Peptide.
- Pericardial effusion.
- Elevated right atrial size and pressure.
- Significant right ventricular dysfunction or failure.
- Low cardiac index.
- Decreased pulmonary arterial capacitance.
- Underlying Scleroderma or liver disease.
References
- ↑ Hopkins WE,Ochoa LL, Richardson GW, Trulock EP(1996) Comparison of the hemodynamics and survival or patients with severe pulmonary hypertension or Eisenmenger Syndrome.